Ranbaxy Denies Fraudulent Conduct Alleged By FDA As Rumors Swirl About Daiichi Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Charges stem from 2006 inspection issues Daiichi knew about when it offered to buy a majority stake in the Indian firm.